Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10997351 | 0.87 | KMT2A (0.46) | KMT2AMEN1MAPK1GAAMAPK10 | |
| SCHEMBL4896376 | 0.86 | MAPK1 (0.43) | KMT2AMEN1MAPK1GAANPSR1 | |
| SCHEMBL22917929 | 0.81 | KMT2A (0.50) | KMT2AMEN1MAPK1GAAMAPT | |
| SCHEMBL4543344 | 0.78 | CHEK1 (0.40) | — | |
| SCHEMBL24512968 | 0.77 | KMT2A (0.49) | KMT2AMEN1MAPK1GAAMAPT | |
| SCHEMBL4904367 | 0.76 | KMT2A (0.48) | KMT2AMEN1MAPK1GAAMAPK10 | |
| SCHEMBL9836815 | 0.75 | KMT2A (0.43) | KMT2AMEN1MAPK1GAAMAPK10 | |
| SCHEMBL9873231 | 0.75 | KMT2A (0.50) | KMT2AMEN1MAPK1GAAMAPK10 | |
| SCHEMBL24512718 | 0.75 | KMT2A (0.50) | KMT2AMEN1MAPK1NPSR1RXFP1 | |
| SCHEMBL2723785 | 0.74 | GAA (0.57) | KMT2AMEN1MAPK1GAAMAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070913-A1 | Thieno [ 3,2-b] pyridine-6-carbonitriles and thieno [2,3-b] pyridine-5-carbonitriles as protein kinase inhibitors | BOSCHELLI DIANE H | 2008-03-20 | — | — | US | disclosed |
| US-7276519-B2 | Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors | WYETH (US) | 2007-10-02 | — | — | US | disclosed |
| US-6987116-B2 | Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors | WYETH (US) | 2006-01-17 | — | — | US | disclosed |
| EP-1565474-A2 | THIENO[3,2-B]PYRIDINE-6-CARBONITRILES AND THIENO[2,3-B]PYRIDINE-5-CARBONITRILES AS PROTEIN KINASE INHIBITORS | Wyeth (US) | 2005-08-24 | — | — | EP | disclosed |
| WO-2004048386-A9 | THIENO[3,2-b]PYRIDINE-6-CARBONITRILES AND THIENO[2,3-b]PYRIDINE-5-CARBONITRILES AS PROTEIN KINASE INHIBITORS | WYETH CORP (US) | 2005-07-14 | — | — | WO | disclosed |
| US-20040242883-A1 | Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors | WYETH | 2004-12-02 | — | — | US | disclosed |
| US-20040138251-A1 | Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors | WYETH | 2004-07-15 | — | — | US | disclosed |
| WO-2004048386-A2 | THIENO[3,2-b]PYRIDINE-6-CARBONITRILES AND THIENO[2,3-b]PYRIDINE-5-CARBONITRILES AS PROTEIN KINASE INHIBITORS | WYETH (US) | 2004-06-10 | — | — | WO | disclosed |
| EP-0046990-A2 | 2-Halogeno-4-alkyl-4,7-dihydro-7-oxo-thieno(3,2-b)-pyridine-6-carboxylic acids, salts thereof at the carboxyl group, pharmaceutical use thereof, and intermediates thereof | KANEBO, LTD. (JP) | 1982-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070913-A1 | Thieno [ 3,2-b] pyridine-6-carbonitriles and thieno [2,3-b] pyridine-5-carbonitriles as protein kinase inhibitors | PKN2, TNNI3K, PKN1 | KMT2A 2822/4885MEN1 1119/4885MAPK1 136/4885 |
| US-20040242883-A1 | Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors | PKN2, PTK2B, PKN1 | KMT2A 2753/4885MEN1 1175/4885MAPK1 64/4885 |
| US-20040138251-A1 | Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors | PTK2B, PKD1, PKN1 | KMT2A 3449/4885MEN1 710/4885MAPK1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.